FIELD: biotechnology.
SUBSTANCE: invention relates to a composition of an anticancer vaccine for transdermal administration for use in inducing cell-mediated immunity, where cancer overexpresses WT1. Said composition contains an effective amount of peptide WT1 and/or modified peptide WT1, selected from a group consisting of peptide Db126, peptide RYF and peptide AYL. Also, said composition contains an effective amount of a first stimulator of induction of cellular immunity, which is a pharmacologically acceptable acid or pharmacologically acceptable salt thereof, where the acid is selected from a group consisting of isostearic acid, decanoic acid, myristic acid and malic acid.
EFFECT: invention enables efficient induction of cell-mediated immunity against cancer.
9 cl, 2 dwg, 7 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ANTICANCER VACCINE COMPOSITION CONTAINING WT1 PEPTIDE FOR TRANSDERMAL ADMINISTRATION | 2014 |
|
RU2687144C2 |
| ANTI-CANCER VACCINE PREPARATION CONTAINING PEPTIDE WT1 IN THE FORM OF A TRANSDERMAL INTRODUCTION TAPE | 2014 |
|
RU2697443C2 |
| VACCINE COMPOSITION AGAINST MALIGNANT TUMOR BASED ON PEPTIDE WT1 FOR MUCOSAL INTRODUCTION | 2014 |
|
RU2687026C2 |
| TOLL-LIKE RECEPTOR 7 OR 8 AGONIST AND CHOLESTEROL COMPLEX AND ITS USE | 2020 |
|
RU2790702C1 |
| MEDICAMENT | 2016 |
|
RU2709015C2 |
| METHODS FOR INCREASING EFFECTIVENESS OF ANTITUMOUR IMMUNE RESPONSE | 2015 |
|
RU2689162C2 |
| CONJUGATE VACCINE ON BASIS OF ANTIGEN WT1 PEPTIDE | 2014 |
|
RU2668560C2 |
| DETERMINATION OF DOSE FOR IMMUNOTHERAPEUTIC AGENTS | 2017 |
|
RU2771717C2 |
| CYTOTOXIC T-CELL (CTC) INDUCING PEPTIDE, METHOD OF INDUCING CTC, ANTIBODY BOUND TO SAID PEPTIDE, USE OF SAID PEPTIDE IN PHARMACEUTICAL COMPOSITION AND FOR TREATING OR PREVENTING CANCER, ANTIGEN-PRESENTING CELL | 2006 |
|
RU2424247C2 |
| USE OF EP4 RECEPTOR ANTAGONISTS FOR TREATMENT OF NASH-ASSOCIATED LIVER CANCER | 2017 |
|
RU2717331C2 |
